Shire Dilip Shantilal Shanghvi is Founder and MD ofSun Phamaceuticals, words fifth and India's largest generic drug producer. One of India's richest self-made businesspeople, ninth according to FORBES in July 2021 with current net worth of US $13.7 billion. From a few psychiatry drugs in 1980s and 10,000 rupees in hand to having its own research and manufacturing facilities by 1994, Sun Pharma scaled heights through series of acquisitions, biggest being Ranbaxy Laboratories. His recent investments include renewable energy, oil and gas.

HIS Contribution to Healthcare Landscape in India ;

* Sun Pharmaceutical Advanced Research Company-SPARC is the first ever pure R&D
Company enlisted with India's stock exchanges.
* Notable International acquisitions include Caraco Pharma of US in 1997, Taro Pharma of Israel in 2007, a dozen other companies and finally Ranbaxy in 2015 valued at around $4 billion, overtaking Mukesh Ambani as the richest man of India.

Change-Making Positions Held ;

* A trustee of the Rhodes Scholarship at Oxford University in 2017.
* Ranked eighth by India Today in India's most powerful people's list of 2017.
* His inspirational Biography "The Reluctant Billionaire" by Soma Das nominated for
Tata Literature Award in Best Business Book Category in 2019.
* A board member of the Reserve Bank of India in 2018.

Laurels Brought to Shree Dilip Shanghvi ;

* Conferred Padma Shri hy the Government of India in 2016.
* Forbes Entrepreneur for the year 2014.
* Ranked by Forbes amongst Asia's Fab 50 companies in 2013.

Impact Brought in the Lives of Common Indians and to People Worldwide ;

Mr. Shanghvi's extraordinary journey from working in his father's small wholesale shop to creating of an unrivalled empire inspires billion dreams. Sun Pharma's global presence across six continents, its workforce comprising over fifty nationalities and high-quality affordable and generic medicines in diversely therapeutic areas trusted by customers of over 150 countries is an outstanding impact.